Photodynamic therapy in the therapy for recurrent/persistent nasopharyngeal cancer by Wildeman, Maarten AM et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
Head & Neck Oncology
Open Access Review
Photodynamic therapy in the therapy for recurrent/persistent 
nasopharyngeal cancer
Maarten AM Wildeman*, Heike J Nyst, Baris Karakullukcu and Bing I Tan*
Address: Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 
Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands
Email: Maarten AM Wildeman* - m.wildeman@nki.nl; Heike J Nyst - h.nyst@nki.nl; Baris Karakullukcu - h.karakullukcu@nki.nl; 
Bing I Tan* - i.tan@nki.nl
* Corresponding authors    
Abstract
To determine the efficacy of Photodynamic therapy of patients with recurrent Nasopharyngeal
Carcinoma we reviewed all available literature.
Since the treatment options for recurrent or persistent Nasopharyngeal Carcinoma are limited, the
survival rates poor and the complications severe; there is definitely a place for alternative treatment
modalities with more efficacy and less morbidity. Photodynamic therapy (PDT) has the potential to
be a very effective local treatment modality for recurrent or persistent nasopharyngeal cancer,
without the severe side effects seen with re-irradiation. This review shows all reported results of
Photodynamic therapy in the treatment for Nasopharyngeal Carcinoma.
Introduction
Nasopharyngeal carcinoma (NPC) occurs sporadically in
the Western world, but is endemic in certain parts of
South-East Asia, such as southern China and the Indone-
sian archipelago [1]. The worldwide incidence of NPC
exceeds 80.000 cases/year with 19,616 new cases each
year in South-China [2], but for most developing coun-
tries data are lacking due to absent or inadequate regis-
tries.
Treatment for primary NPC is radiotherapy, with chemo-
therapy for advanced stage disease. Despite the radiother-
apy responsiveness of nasopharyngeal tumours, good
long term survival is only achieved for patients who have
early primary tumours with minimal neck disease with
67-71% 10 years disease free survival for T1, T2 and N0-1.
Survival is poor for patients who have extended tumours
and/or extended neck nodes 29-54% 10 years disease free
survival for T3, T4 and N2, N3) [3-6].
Poor survival in the T4N0-1 category is chiefly the result
of the high local recurrence rate (63.8%), where as for the
T1-2N2-3 category, it is the result of the high distant
metastases rate (approximately 50%). For the local recur-
rent or persistent tumours there are few treatment options
left all with severe side effects.
Re-treatment of recurrent/persistent NPC
Usual treatment options for early stage recurrent or per-
sistent NPC are surgery in combination with external radi-
otherapy, brachytherapy alone [7-9], or in combination
with external re-irradiation [10-13] or stereotactic radio-
surgery [14]. The standard treatment for advanced stages
of recurrent or persistent disease is chemotherapy fol-
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lowed by re-irradiation, or concomitant chemo-re-irradia-
tion [15]. Pryzant reported on 53 patients with locally
persistent or recurrent NPC treated with re-irradiation.
Forty-two patients were re-treated with external beam
therapy alone and 11 with a component of brachytherapy.
Local recurrence was confined to the nasopharynx in 27
patients, and persistent tumour in 26 patients. The five-
year actuarial local tumour control rate was 35%, five-year
disease free survival was 18%, and overall survival was
21%. Eight Patients developed severe complications from
retreatment, two involving the brain, one the spinal cord,
and two the cranial nerves, all of which were fatal. The
five-year actuarial incidence of severe complications was
17%. The incidence of severe complications was related to
the total cumulative dose of external irradiation [16].
Lee described the incidence of late complications after re-
irradiation in 891 patients with local recurrence after
definitive radiation therapy for nasopharyngeal carci-
noma. After external re-irradiation, brachytherapy or a
combination of both, a wide variety of serious complica-
tions, such as temporal lobe necrosis, cranial neuropathy,
endocrine dysfunction, trismus and bone/soft tissue
necrosis was reported, with an overall incidence of 23 to
29% and a treatment mortality from 1 to 3% [17]. Other
authors also report these serious side effects [10-12]. A
major determinant of post-treatment complication is the
severity of damage sustained during the initial course. In
case of re-irradiation after an interval of 2 years or more,
the sum of total doses tolerated is higher than predicted
based on results of single course irradiations [18].
Since the treatment options for recurrent or persistent
NPC are limited, the survival rates poor and the complica-
tions severe; there is definitely a place for alternative treat-
ment modalities with more efficacy and less morbidity.
Photodynamic Therapy
Photodynamic therapy (PDT) is a non-invasive treatment
modality that might have a substantial role in treatment
of recurrent nasopharyngeal carcinoma. PDT facilitates
tumour destruction by the combination of a photosensi-
tizer and laser light of a specific wavelength.
The therapeutic response of PDT depends on a complex
combination of parameters that includes drug dose, drug-
light interval, tissue oxygenation, light dose and light
intensity (the last two are more accurately referred to as
fluence and fluence rate, respectively). PDT works through
non thermal chemical pathways to damage cancer cells.
The main agents of cell destruction are activated singlet
oxygens. The cancer cells are destroyed by a process that
might take up to several weeks and the treated area heals
with normal mucosa advancing from adjacent tissue
much like radiation treatment.
Photodynamic Therapy for Recurrent and 
Persistent NPC
Sun [19] has published the largest case series with 137
patients. Unfortunately this article is in Chinese. He has
treated 137 NPC patients with hematoporphyrin deriva-
tive mediated PDT. Forty-eight and 72 hours after iv
administration of 3-5 mg/kg HpD, laser treatment with
either argon or dye laser was carried out. Dye laser (630
nm) with over 350 mw output transmitted through quartz
fiber was given to 57 patients. Argon laser (488 nm and
514.5 nm) was delivered to 80 patients. The results were:
complete response 76 cases (55.47%) and marked
response 47 cases (34.31%), with an over-all marked
response rate of 89.78% (123/137). These results are very
successful. However, it is not clear if the patients had
recurrent NPC or PDT is delivered as primary first choice
treatment. In either case the results are very encouraging
with such a large case series.
Kulapaditharom [20]et al reported in 1996 five patients
treated with PDT for recurrent or residual NPC in Ramath-
idoni hospital in Bangkok. Three of these patients had a
T1 tumour with no lymph node involvement and no dis-
tant metastasis. Two of these patients had a T3 tumour
with no lymph node involvement and no distant metas-
tases. 48 hours before illumination patients received
Hematopirfyrin derivate with a dosage of 3 mg/kg and
were illuminated (630 nm) by an optical fiber. The dose
varied within 50-100 J/cm2. Power of the laser beam was
adjusted to give a density within 100-150 mW/cm2 to
avoid thermal effect.
The T1 tumour patients had a complete response after one
treatment. Complete response has been suggested by
endoscopic examination and negative biopsy. The dura-
tion of response were: 24, 16 and 11 months. The T3
tumours responded partially. One patient received 4 treat-
ments and the other one 2 treatments before they
switched to chemotherapy. The partial response duration
was respectively 19 and 12 months.
The side effects described for all treatment were oedema,
pain and photosensitivity. All side effects would solve
without treatment. There was one patient with severe pain
after PDT. All other side effects were mild and moderate.
The same Kulapaditharom [21] et al reported in 2000 the
treatment of 12 NPC patients. The patients received
Hematopirfyrin derivate with a dosage of 3 mg/kg 48
hours before they were illuminated (630 nm) by an flat
cut optical fiber (with a core diameter of 400 μm, Laser-
scope California) with a with a dose of 100 J/cm2 and a
fluence rate of 100 mW/cm2.
One patient was primary treated for an unknown primary.
The primary tumour revealed in the nasopharynx (T1 NOHead & Neck Oncology 2009, 1:40 http://www.headandneckoncology.org/content/1/1/40
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MO) and because this patient already received radiother-
apy and neck dissection he was treated with PDT. Com-
plete response as observed for a follow up period of 31
months.
Six patients were treated for recurrent or residual T1-T2
NPC without lymph nodes and distant metastasis. These
patients had received chemo-radiation for initial treat-
ment. All patients had a biopsy and endoscopic complete
respons after PDT treatment. Duration respons was
between 10 and 66 months, mean duration was 26,5
months. One patient died 12 months after PDT cause of
an unrelated cause.
One patient had a residual T3N0M0 adenoid cystic carci-
noma instead of squameus cell carcinoma. Patient was
treated with PDT and surgery. Patient had a partial
response and has been symptom free for 22 months.
Four patients received PDT as adjunct to conventional
treatment; these patients were all T3-T4 patients. One
received radiotherapy, the other three received 6 cycles of
chemotherapy. Three patients had a partial response and
one had a complete response.
Tong [22]et al reported 12 patients treated with PDT for
recurrent NPC in Prince of Wales Hospital in Hong Kong.
These patients were treated with hematoporphyrin deri-
vate 5 mg/kg and exposed with 200 J/cm2 delivered from
a gold laser vaper with a wave length of 630 nm.
In eight patients cure of disease was deemed possible. The
other four patients were treated for palliation of nasal
obstruction. Four patients received surgical debulking
before PDT. All patients showed radiology confirmed
tumour regression six months after treatment. From the
eight patients treated for cure five patients had a residual
disease after 3-5 months, the other three remained disease
free with a follow up between 9-12 months. Four patients
had nasal regurgitation and two patients had their trismus
aggravated, these side effects were temporarily. Two
patients had mild skin hypersensitivity.
Lofgren [23]et al reported 5 patients treated with PDT for
recurrent or persistent NPC in Orebro Medical Center
Hospital, Sweden. Four patients were treated with hemat-
oporphyrin derivative 2.5 mg/kg. One patient has been
treated with potfimer sodium 2.0 mg/kg. The light dose
varied from 50 to 100 J/cm2 and radiance varied from 100
to 150 mW/cm2.
Four patients had SCC, two of them had a recurrence and
two of them persistent disease. One patient had a persist-
ent adenocarcinoma. All patients were initially treated
with radiotherapy.
Three patients remain tumour free with a follow up
between 51 and 60 months. These patients had a tumour
depth of 10 mm or less. One patient had persistent disease
after PDT, a MRI-scan showed after treatment a tumour
depth of 13 mm. One patient had a recurrence 6 months
after treatment.
All patients had significant headache (3 to 8 months) and
middle ear effusion. Two patients experienced minor
problems of photosensitivity after sun exposure five 40
days after treatment (Additional file 1).
Discussion
PDT has the potential to be a very effective local treatment
modality for NPC, without the severe side effects seen
with radiotherapy.
The articles above have shown that PDT is effective in
destroying NPC, with good local control of tumor growth
and complete responses in the majority of small recurrent
or persistent disease (T1, T2) and long-term palliation in
advanced stage (T3, T4) of the recurrence.
There are several advantages of PDT for management of
recurrent NPC. Perhaps the most important advantage is
its repeatability. PDT does not have cumulative effects. In
case of a partial response the same area can be illuminated
again. Secondly PDT is a local treatment rather than a sys-
temic one. The photosensitizing drug accumulates in
higher concentrations within cancer cells rendering them
more susceptible to the toxic effects of light, compared to
normal healthy cells and the light is delivered directly
onto the tumour sparing the surrounding normal mucosa.
Two other advantages of PDT are normal healing of the
wound and illumination is only once.
In the papers reviewed above they all used the first gener-
ation photosensitizer hematoporphyrin. Yow [24] et al
has shown in nasopharyngeal cancer cell lines that the
uptake of second generation potosensitizer temaporfin is
higher and efficiency is better compared with hematopor-
phyrin. Yow [25]et al also compared temoporfin and
merocyanine 540, both second generation photosentisiz-
ers. They concluded that temoporfin-mediated PDT has a
more potent effect in comparison with merocyanine- 540-
mediated PDT. Based on these studies we hope for even
better treatment results if temoporfin is used.
Illumination of nasopharyngeal cavity is a challenge,
since access is difficult and the cavity has a complex and
irregular geometry. Furthermore the cavity varies signifi-
cantly in size and geometry between patients. The com-
plex shape of the nasopharyngeal cavity makes it
impossible to produce a homogenous field of illumina-
tion. In order to deliver a sufficient light distributionHead & Neck Oncology 2009, 1:40 http://www.headandneckoncology.org/content/1/1/40
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throughout the nasopharyngeal cavity over exposure can-
not be avoided. Over exposure of tumour or surrounding
normal mucosa is however not considered a problem.
Some critical structures are well protected by bone others;
however, like the soft palate and the dorsal oropharyngeal
wall would suffer unacceptable damage by this approach.
Hence, these areas must be shielded against the laser light.
For this purpose we have developed a novel dedicated
light delivery applicator that ensures proper light delivery
to the target area and enables for proper shielding of the
risk areas [26,27]. A new study has been commenced to
use this applicator to deliver PDT to patients with recur-
rent NPC cancers by our group. How we illuminate the
Nasopharynx is shown by Figure 1, 2, 3.
The side effects are much less frequent and severe com-
pared to chemotherapy. Sunlight exposure have shown
that photosensitivity is not a real burden for these patients
and only limited adverse events were related to this prob-
lem [28]. In general, patients in this part of the world have
a colored skin that makes them less prone to sunburn. The
fact that people in the tropics generally avoid sun expo-
sure also helps to minimize the problems around the pho-
tosensitivity.
The immunologic reaction followed by PDT could be
partly responsible for the good results. The theory is that
an immunological response will be provoked by the use
of PDT [29]. So in addition to these clinical trials several
groups are working on the effectiveness of PDT in labora-
tory settings. PDT and the use of natural compounds
become one of the new approaches in the investigation of
NPC treatment. Such a group from Singapore has reported
very encouraging results with hyperecin mediated PDT.
This group has published extensively on biochemical
pathways of cell damage caused by hypericin-PDT on
NPC cell lines in vitro. Their excellent review titled "
Hypericin lights up the way for the potential treatment of
nasopharyngeal cancer by photodynamic therapy" by
Olivo [30] et al summarizes this effort and proposes that
hypericin-PDT is a potential treatment of NPC in humans.
Koon [31] et al has chosen a different photosensitizing
agent from the traditional Chinese medicine: curcumin.
Their in vitro study with CNE2 NPC cells shows it to be a
promising agent.
Xu et al[32] preferred to worked with photodynamic
effects of pyropheophorbide-a methyl ester (MPPa) in
CNE2 NPC cells, demonstrating the apoptotic effect and
suggesting its clinical potential. Mak et al[33] worked with
A: Nasopharynx applicator, B: schematic view of positioning  and illumination Figure 1
A: Nasopharynx applicator, B: schematic view of 
positioning and illumination. 1. Cylindrical diffuser in 
shielding tube. 2. Target area. 3. Soft palate is shielded. Figure 
1 have beenused previously by Nyst et al, 2007 [26]
Insertion of the Nasopharyngeal Applicator Figure 2
Insertion of the Nasopharyngeal Applicator.Head & Neck Oncology 2009, 1:40 http://www.headandneckoncology.org/content/1/1/40
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the same cell line inducing phototoxicity with sulfona-
mide derivatives of porphycene with successful results.
Betz [34] et al obtained good results in their in vitro study
with amore conventional photosensitizer: 5-aminole-
vulinic acid.
Bae [35] et al examined the immunotherapeutic signifi-
cance of HPV-immortalitized tumour cell lysates induced
by PDT and CpG-oligodeoxynucleotide(ODN). They
found a significant induced IFN-β production and cyto-
toxic T- cell response in the PDT-cell lysate plus ODN
immunized groups. Although PDT in combination with
immunotherapy is still in experimental fase it offers a
great promise as a new alternative treatment. On to this
time no research has been done on PDT in combination
with Immunotherapy in EBV related NPC. This combina-
tion could be very promising not only for local recurrence
but also for advanced disease.
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